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Introduction
1,4-Benzodiazepin-2-ones are privileged structures possessing an outstanding range of important medicinal and pharmaceutical properties 1 including uses as gastrin/cholecystokinin-B antagonists, 2 anticonvulsant, 3 anxiolytic agent, 4 anti-HIV, 5 and HIV-Tat antagonist, 6 oxytocin antagonist, 7 anti-ischemic agents, 8 neuroprotective effect, 9 and antitrypanosomal activity. 10 In addition, the treatment of neurologic disorders such as Down's syndrome and Alzheimer's disease has been successfully completed by employing these heterocyclic families.
11 Several palladacycle complexes derived from 1,4-benzodiazepin-2-ones and pyrrolo[2,1-c][1,4]benzodiazepinones were found to be potent antitumor agents, 1b,12 whilst another benzodiazepine surrogates were used as antileishmanial agents. 13 But 1,4-benzodiazepin-2-ones and its analogues are predominantly active in the central nervous system. For example, it has been reported potent nonpeptidal receptor antagonist of the peptide hormone cholecystokinin, 14 the selective cholecistokinine-A (CCKA) antagonist MK-329 1, 15 and the selective cholecistokinine-B (CCKB) antagonists L-365,260 2, 16 and YM022 3 17 and a selective translocator protein (TSPO) agonist Ro5-4864 4 ( Figure  1 ). 8, 9, 18 Recently, there have been reported many synthetic strategies to investigate novel and/or structurally diverse privileged scaffold containing 1,4-benzodiazepin-2-one frameworks. The most employed strategy consist in the synthesis of the fully functionalized heterocycle. Alternatively, benzodiazepine-2-ones can be used as the pharmacophore whose substituents are ready to be introduced or modified by conventional synthetic procedures. In this sense, we have reported that an amino group bonded to the 3-position of benzodiazepine ring reacted with aldehyde to generate the corresponding imine, which was the precursor of the azomethine ylide via thermal or by metal-catalyzed processes. In this contribution, 1,3-dipolar cycloaddition cascade reactions occurred with chiral and achiral dipolarophiles affording spirocycloadducts in good to excellent yields. 20 In addition, Grigg's group experience concerning multicomponent 21 palladium cascades (A→B→C) have been widely demonstrated, 22 especially, in those involving oxidative addition-intermolecular allene insertion (Scheme 1, eq. a) or carbon monoxide insertion (Scheme 1, eq. b) followed by nucleophilic addition as terminating reactions.
22a,c,h,e,23,24 Scheme 1. Domino reactions involved in this contribution.
In this work, novel 1,4-benzodiazepine-2-one analogues are synthesized from benzodiazepine-2-one precursors via palladium(0)-catalyzed multicomponent reactions based on oxidative addition onto species A, followed by allene B insertion and final capture with nucleophile C, as well as oxidative addition onto species A followed by carbon monoxide B insertion and final capture with nucleophile C. In all cases, and according to Scheme 1, the terminating step is performed through the amino/amido group anchored to the benzodiazepine-2-one nucleus.
Results and Discussion

Palladium(0)-catalyzed allenylation-anion capture cascade reactions:
The three-component reaction involving free amine 1-methyl-3-amino-1,3-dihidro-5-phenyl-(2H)-1,4-benzodiazepine-2-one 5, 22 ,23 aryl halides 6 and allene 7a was performed in the presence of a catalytic system comprised by Pd 2 (dba) 3 (10 mol%) and PPh 3 (20 mol%). The final conditions were selected according to previous optimizations done in previous works, 22b,c that means, DMF at 70 º C for 24-36 h and K 2 CO 3 as base (2 equiv). Compounds 8a-d were obtained in 84-90% yield (Scheme 2). Using this methodology, the incorporation of new biologically interesting substituents, as 5-uracyl 25 or 2-thienyl, 26 was available increasing the potential activity of products 8a-d. A second version of this cascade palladium-catalyzed allenylation-anion capture was successfully attempted with benzodiazepinone 9a as nucleophilic terminating agent. 27 Using identical reaction conditions than those described before, substituted and unsubstituted allenes 7 were allowed to react with aryl halides 6 and heterocycle 9a, in the presence of Pd 2 (dba) 3 (10 mol%) and PPh 3 (20 mol%) in DMF at 80 º C for 48 h. Functionalized compounds 10a-d were obtained in 65-92% yield in one pot cascade reaction (Scheme 3). X-Ray diffraction analysis of structure 10a 28 also confirmed the skeleton drawn in Scheme 3.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Palladium-catalyzed carbonylation-anion capture cascade reactions: A third series of benzodiazepine-2-one analogues were prepared from 5 or 9 but employing carbon monoxide instead of allenes as relay species in the cascade processes. These reactions were accomplished with potassium carbonate (1.2 equiv) and a catalytic system comprised by palladium(II) acetate (10 mol%), and triphenylphosphine (20 mol%) in toluene at 110 º C for 26 h. First, amine 5 was employed as terminating agent in the palladium(0)-catalyzed oxidative addition-carbonylation obtaining products 11a and 11b in 89% and 81% yields, respectively (Scheme 3, eq. a). Similarly, benzodiazepine-2-ones 9a (X = H) and 9b (X = Cl) 29 were submitted to palladium catalyzed carbonylation anion capture reaction affording products 12a and 12b in 73% and 89% yields, respectively (Scheme 3, eq. b). Despite of being a trivial transformation introducing a benzoyl group, this procedure permit the use of more complex iodoarenes, which are much more accessible than the corresponding benzoyl chlorides. In this series a variety of reactions conditions were evaluated, such as different catalyst systems, but yields were not improved. An example of double relay system in a palladium-catalyzed cyclization-carbonylation-anion capture reaction was studied. Thus the aryl iodide 13 30 smoothly reacted with palladium(II) acetate (10 mol%) and triphenylphosphine (20 mol%), of potassium carbonate (1.2 equiv) in toluene at 100 o C for 26 h furnishing product 14 in 78% yield as a 1:1 mixture of diastereoisomers (Scheme 5). A similar ratio was observed in the earlier stages of the reaction, even at low temperatures. The reaction proceeds via 5-exo-trig cyclisation as starting process of the palladium cascade reaction. 31 Both isomers were separated by column chromatography (flash silica) and one of them (anti-14) completely characterized after analysis of X-ray diffraction of a monocrystal structure 32 (Scheme 5).
Scheme 5.
Palladium-catalyzed cyclization-carbonylation-anion capture from compounds 5 and 13 and X-ray diffraction structure of diastereoisomer anti-14.
Conclusion
In conclusion, a variety of 1,4-benzodiazepine-2-one derivatives can be accessed through a simple one-pot molecularly diverse multicomponent cascade protocol proceeding via palladium(0)-catalyzed allenylation anion capture and cascade palladium-catalyzed carbonylation anion capture reactions. In these processes C(sp 2 )-C(sp 2 ) + C(sp 3 )-N(sp 3 ) new bonds and C(sp 2 )-C(sp 2 ) + C(sp 2 )-N(sp 3 ) new bonds are generated, respectively. In addition, with a double relay system, C(sp 2 )-
new bonds are easily formed using the appropriate starter. With this methodology a range of allenes and aryl halides can be employed in good to excellent yields tolerating many functional groups. The molecular complexity of each component can be increased in order to build sophisticated architectures or even natural core products.
Experimental Section
General information
Melting points were determined on a Kofler hot stage apparatus and are uncorrected. Mass spectra were recorded at 70 eV on a VG Autospec mass spectrometer. Nuclear magnetic resonance spectra and decoupling experiments were determined at 250 MHz M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT on a Q.E 300 instrument and at 500 MHz on a Bruker AM500 spectrometer as specified. Chemical shifts are given in parts per million (δ) downfield from tetramethylsilane as internal standard. Spectra were determined in CDCl 3 except where otherwise stated. The structurally most important peaks of the IR spectra (recorded using a Nicolet 510 P-FT-ATR) are listed and wavenumbers are given in cm -1 . Flash column chromatography was performed using silica gel 60 (230-400 mesh). Kieselgel columns were packed with silica gel GF254 (Merck 7730). Petroleum ether refers the fraction with bp 40-60 ºC unless otherwise specified. Microanalyses were obtained using a CarloErba Model 1106 instrument. Arylhalides were purchased from Aldrich and used as received. In the case of aryliodide 13 was prepared according to literature procedure. 30 
Synthetic procedures and characterization data 4.2.1. General procedure for allenylation-anion capture reaction. Synthesis of compounds 8
In a Shlenk tube a solution of aryl halide (1.2 mmol), Pd 2 (dba) 3 (92 mg, 0.1 mmol), PPh 3 (52 mg, 0.2 mmol) and K 2 CO 3 (276 mg, 2 mmol) in dry DMF (10 mL) was prepared. Then free amine 5 (318, 1.2 mmol) was added and the mixture was degassed once by the freeze thaw pump. Allene was introduced (1 atm) and the solution stirred at 70 ºC for 24-36 h. The Schlenk was cooled to ambient temperature and internal pressure was released slowly before filtering the crude mixture through a filter paper. The solvent was evaporated under reduced pressure to give a solid which was purified by column chromatography (flash silica) obtaining compounds 8. 
3-[2-Phenyl-2-propenyl)amino]-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (8a
(26). HRMS (ES)
: C 27 H 25 N 3 O 2 Na requires: 446.1844, found: 446
1,3-Dimethyl-5-(1-{[1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) amino] methyl}vinyl)-2,4 (1H, 3H)-pyrimidinedione (8d
General procedure for allenylation-anion capture reaction. Synthesis of compounds 10
The method to prepare compounds 10 was the analogous one described for the synthesis if compounds 8 but employing K 2 CO 3 (130 mg, 1.2 mmol) at 80 ºC for 48 h. MHz 
5-Phenyl-1-(2-phenyl-2-propenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (10a):
1,3-Dimethyl-5-{1-[2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)vinyl}-2,4(1H,3H)-pyrimidinedione (10b):
5-Phenyl-1-[2-(2-thienyl)-2-propenyl]-1,3-dihydro-2H-1,4-benzodiazepin-2-one (10c):
1-[3-Methyl-2-(2-thienyl)-2-butenyl]-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (10d)
:
General procedure for the carbonylation anion capture reaction. Synthesis of compounds 11, 12 and 14.
A solution of iodoarene 6 or 13 (1.1 mmol), Pd 2 (dba) 3 (92 mg, 0.1 mmol), PPh 3 (52 mg, 0.2 mmol) and K 2 CO 3 (166 mg, 1.2 mmol) and the corresponding benzodiazepine-2-one derivative 5 or 9 (1 mmol) in dry toluene was prepared in a round-bottomed flask. Then, a balloon containing carbon monoxide was adapted and the mixture heated to 100-105 ºC for 24-32 h. The reaction was cooled to ambient temperature and filtered through filter paper. The solvent was evaporated under reduced pressure to give a solid which was purified by column chromatography (flash silica) obtaining pure compounds 11, 12 and 14. 2-(1,3-Dimethyl-2-oxo-2,3)-dihydro-1H-indol-3-yl)-N 
N-[1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) benzamide (11a):
